<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783142</url>
  </required_header>
  <id_info>
    <org_study_id>20-008067</org_study_id>
    <nct_id>NCT04783142</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Influence of Diet on GI Health</brief_title>
  <official_title>The Influence of Diet on Host Physiology and Disease Across Diverse Human Gut Microbiotas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the potential of protein and psyllium fiber to&#xD;
      manipulate gut microbial densities, intestinal permeability, and inflammation in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomly assigned to either the high-fiber, low protein diet or the low-fiber, high-protein diet.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Principal investigator and analysts will be blinded. The participant will not be told to which diet they are randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Excretion of Lactulose and 13C-Mannitol</measure>
    <time_frame>4 weeks</time_frame>
    <description>Small Bowel and Colonic Permeability by Urinary Excretion of Lactulose and 13C-Mannitol after Oral Ingestion of lactulose and 13C mannitol (5:1 ratio by mass). The 0-2h urine most closely reflects small intestinal permeability and 8-24h urine reflects colonic permeability. HPLC-tandem mass spectrometry will be used for detection of the sugars. The results will be expressed as the ratio of percentage excretion of the ingested dose of lactulose and mannitol in urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbial alpha diversity based on Shannon index</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool samples will be processed to extract DNA, followed by metagenomic sequencing and assessment of alpha diversity using Shannon index. Comparison will be made using ttest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High-fiber, low-protein diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will consume a high-fiber, low-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-fiber, high-protein diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will consume a low-fiber, high-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-fiber, low-protein diet</intervention_name>
    <description>Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.</description>
    <arm_group_label>High-fiber, low-protein diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-fiber, high-protein diet</intervention_name>
    <description>Diet will consist of less than 15g fiber and greater than 18% of calories from protein</description>
    <arm_group_label>Low-fiber, high-protein diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years old&#xD;
&#xD;
          -  On a baseline diet characterized by: Fiber intake of &lt; 15g/day, &gt; 18% of daily&#xD;
             calories from protein&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy)&#xD;
&#xD;
          -  Known diagnosis of inflammatory bowel disease (Crohn's or ulcerative colitis),&#xD;
             microscopic colitis, celiac disease, or other inflammatory GI condition&#xD;
&#xD;
          -  Use of tobacco products within the past 6 months (since nicotine may affect intestinal&#xD;
             permeability)&#xD;
&#xD;
          -  Use of NSAIDs or aspirin and unable or unwilling to stop taking two weeks prior to&#xD;
             permeability test and for the duration of the study&#xD;
&#xD;
          -  Use of osmotic laxatives and unable or unwilling to stop taking one week prior to&#xD;
             permeability test and for the duration of the study&#xD;
&#xD;
          -  Use of oral corticosteroids and unable or unwilling to stop use of oral&#xD;
             corticosteroids within the previous 6 weeks and for the duration of the study&#xD;
&#xD;
          -  Multiple dietary restrictions or unable/unwilling to alter dietary protein or dietary&#xD;
             fiber.&#xD;
&#xD;
          -  Unwilling to stop ingestion of alcohol and artificial sweeteners such as Splenda™&#xD;
             (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days&#xD;
             before and during the permeability testing days, e.g. foods to be avoided are&#xD;
             sugarless gums or mints and diet beverages&#xD;
&#xD;
          -  Unwilling to stop stenuous exercise (running &gt;5 miles or equivalent) one week prior to&#xD;
             the permeability tests&#xD;
&#xD;
          -  Bowel preparation for colonoscopy less than one week prior to completion of the first&#xD;
             stool kit and permeability test and flexible sigmoidoscopy and upper endoscopy&#xD;
&#xD;
          -  Pregnancy or plan to become pregnant during the study time frame&#xD;
&#xD;
          -  Vulnerable adult&#xD;
&#xD;
          -  Known bleeding disorders or takes medications that increase risk of bleeding from&#xD;
             mucosal biopsies&#xD;
&#xD;
          -  Use of oral antibiotic(s) within the past 4 weeks (can be enrolled after 4-week&#xD;
             washout period)&#xD;
&#xD;
          -  Use of commercial probiotic formulations and unwilling to stop for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Diagnosis of diabetes&#xD;
&#xD;
          -  Any other disease(s), condition(s) or habits(s) that would interfere with completion&#xD;
             of study, or in the judgment of the investigator would potentially interfere with&#xD;
             compliance to this study or would adversely affect study outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Purna C. Kashyap, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Lekatz</last_name>
    <phone>(507) 538-1206</phone>
    <email>lekatz.heather@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Purna C. Kashyap, MBBS</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator</last_name>
      <phone>507-538-1206</phone>
      <email>lekatz.heather@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Purna C. Kashyap, MBBS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>High-Protein, Low-Fiber Diet</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

